Genomtec (GMT) Q1 2026 earnings summary

Executive summary

• Group operates in biotechnology and medical device R&D, focusing on mobile diagnostic platforms and infectious disease tests.

• No changes in group structure or ownership during the reporting period.

• Shares are publicly traded since February 2023.

Financial highlights

• Consolidated revenue from sales: 16k PLN, up from 5k PLN year-over-year.

• Consolidated net loss: (2,196)k PLN, improved from (3,205)k PLN year-over-year.

• Cash and equivalents at period end: 2,605k PLN, down from 4,722k PLN at year-end 2025.

• Operating cash flow: (1,840)k PLN, improved from (3,357)k PLN year-over-year.

• No dividend paid or declared.

Outlook and guidance

• Ongoing R&D funded by equity, grants, and planned new share issues.

• 2026 grant inflows expected at approx. 15.6m PLN.

• Further share issues may be needed to finance commercialization.

• Profitability expected after commercialization of developed technologies.